Evonik Vland Biotech, a new joint venture between Evonik China and Shandong Vland Biotech, began operations on January 1, 2024. The venture aims to expand the market presence of their livestock probiotics in Greater China and develop new products. The official opening took place in Qingdao on March 14.
Epsilogen and Lonza have successfully completed the manufacturing of a potential cancer treatment. The complex process, which took less than ten months, was carried out at Lonza’s UK site following Good Manufacturing Practice (GMP) standards.
Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and biotechnology, recently announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.
In response to the urgent need for sustainable solutions in the surfactants industry, companies like Locus Ingredients are developing environmentally friendly biosurfactants.
The biopharmaceutical industry is experiencing a drive towards biologic products due to their promise as treatments for chronic diseases.
The pharmaceutical market is undergoing a profound transformation, driven by innovation among biologics and advanced therapies (ATs). This shift is not only redefining the treatment landscape but also presenting new opportunities and challenges related to the drug development and manufacturing value chain.
The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven these capabilities over the past two years by producing Covid-19 vaccines and a significant number of clinical batches for several biological companies. By investing in its competencies, capacities and flexibility, the company intends to further expand this demanding but promising business area.
Science and technology group 3M has announced plans to invest $146 million to expand its biopharma filtration capabilities at manufacturing facilities in Europe. The company did not disclose the facilities’ locations.
Germany’s Merck said this week it has signed a non-binding Memorandum of Understanding (MoU) with South Korea’s Ministry of Trade, Industry and Energy (MOTIE), and Daejeon City to establish a new Asia-Pacific BioProcessing Center.
Purolite, a US manufacturer of ion exchange resins that is also part of Ecolab, has opened up a new facility in Llantrisant, Wales, tripling its bioprocessing resin production. The company said the extra output will meet growing global demand for biopharmaceutical products.
